FDA Panel Backs Replimune's Melanoma Drug 10-3, Defying Staff Concerns
REPL has more than doubled off its 52-week low of $1.5 on elevated volume (2.4× avg).
Summary
An FDA advisory panel voted 10-3 in favor of Replimune's RP1 for advanced melanoma, a surprising outcome after FDA staff raised serious efficacy doubts earlier this week that sent shares down over 30%. The panel acknowledged the data was 'messy' but cited promising responses in patients who had failed prior therapies and compelling patient testimony. This vote dramatically increases the odds of FDA approval by the August 2 decision date, though the agency is not bound by the recommendation. The positive panel vote follows a two-year regulatory saga with multiple rejections and a recent White House push for reconsideration. With a going concern warning and cash only into early 2027, approval would be transformative for Replimune, potentially unlocking the drug's commercial opportunity and easing financing pressure. The stock was halted during the meeting; expect significant volatility when trading resumes.
At the time of this announcement, REPL was trading at $5.41 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $454.2M. The 52-week trading range was $1.50 to $12.50. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Dow Jones Newswires.